Reiva Farah Dwiyana

Dr. Reiva Farah Dwiyana

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
RERaden Mohamad Rendy Ariezal Effendi
Raden Mohamad Rendy Ariezal Effendi
Muhammad AnshoryMuhammad Anshory
Muhammad Anshory
HKHandono Kalim
Handono Kalim
RDReiva Farah Dwiyana
Reiva Farah Dwiyana
OSOki Suwarsa
Oki Suwarsa
HTHok Bing Thio
Hok Bing Thio
Probiotics and synbiotics are used to treat chronic illnesses due to their roles in immune system modulation and anti-inflammatory response. They have been shown to reduce inflammation in a number of immune-related disorders, including systemic lupus erythematosus (SLE), human immunodeficiency virus (HIV), and chronic inflammatory skin conditions such as psoriasis and atopic dermatitis (AD). Akkermansia muciniphila (A. muciniphila) and Faecalibacterium prausnitzii (F. prausnitzii) are two different types of bacteria that play a significant part in this function. It has been established that Akkermansia and Faecalibacterium are abundant in normal populations and have protective benefits on digestive health while also enhancing the immune system, metabolism, and gut barrier of the host. They have the potential to be a therapeutic target in diseases connected to the microbiota, such as immunological disorders and cancer immunotherapy. There has not been a review of the anti-inflammatory effects of Akkermansia and Faecalibacterium, particularly in immunological diseases. In this review, we highlight the most recent scientific findings regarding A. muciniphila and F. prausnitzii as two significant gut microbiota for microbiome alterations and seek to provide cutting-edge insight in terms of microbiome-targeted therapies as promising preventive and therapeutic tools in immune-related diseases and cancer immunotherapy.

21 February 2023 in Fermentation
Verified
Journal Article
Open access
PDF file
Muhammad AnshoryMuhammad Anshory
Muhammad Anshory
RERaden Mohamad Rendy Ariezal Effendi
Raden Mohamad Rendy Ariezal Effendi
HKHandono Kalim
Handono Kalim
RDReiva Farah Dwiyana
Reiva Farah Dwiyana
OSOki Suwarsa
Oki Suwarsa
HTHok Bing Thio
Hok Bing Thio
Butyrate is a short-chain fatty acid (SCFA) created within the intestinal lumen by bacterial fermentation of largely undigested dietary carbohydrates. Its beneficial effects on cellular energy metabolism and intestinal homeostasis have garnered significant attention among SCFAs. Butyrate also has systemic effects and is known to regulate the immune system. Most of the butyrate and other SCFAs are produced in the human colon, through the fermentation of dietary fiber or resistant starch. However, the modern diet often lacks sufficient intake of fermentable dietary fiber, which can lead to low butyrate levels in the colon. To increase butyrate levels, it is helpful to incorporate fiber sources into meals and drinks that rely on slow bacterial fermentation. Butyrate is well known for its anti-inflammatory properties and has a range of immune system-related properties. As an agonist for GPR41, GPR43, or GPR109A, butyrate may have anti-inflammatory effects through these receptors’ signaling pathways. Butyrate also serves as an epigenetic regulator, responding to environmental or pharmacological changes by inhibiting HDAC, up-regulating miR-7a-5p, and promoting histone butyrylation and autophagy processes. This review discusses the importance of butyrate in regulating immunological homeostasis and the inflammatory response. It also addresses experimental models and human studies investigating the therapeutic potential of butyrate supplementation in immune-related conditions linked to butyrate depletion. Specifically, it covers the role of butyrate in some immune-related diseases such as systemic lupus erythematosus, atopic dermatitis, psoriasis, human immunodeficiency virus, cancer, and several other special conditions.

1 September 2023 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
KRKartika Ruchiatan
Kartika Ruchiatan
TRTrustia Rizqandaru
Trustia Rizqandaru
PSPanji Respati Satjamanggala
Panji Respati Satjamanggala
NTNisrina Tache
Nisrina Tache
ACAdi Imam Cahyadi
Adi Imam Cahyadi
RHReti Hindritiani
Reti Hindritiani
Introduction: Acne vulgaris (AV) is a common and chronic disorder of the pilosebaceous unit and has a multifactorial pathology, including activities of Cutibacterium acnes (C. acnes) and Staphylococcus epidermidis (S. epidermidis). Antibiotic resistance has become a major concern in dermatology daily practice, and the ability of biofilm formation by both bacteria is suggested to increase antibiotic resistance in acne. Purpose: Our aim was to analyze the comparison of antibiotic resistance between biofilm-forming (BF) and non-biofilm-forming (NBF) strains of C. acnes and S. epidermidis towards seven antibiotics commonly used for acne. Methods: This is a cross-sectional analytical study involving 60 patients with AV. Samples were obtained from closed comedones on the forehead using the standardized skin surface biopsy (SSSB) method at the Cosmetic Dermatology Clinic Dr. Hasan Sadikin in Bandung, Indonesia. Isolates were cultured and identified before undergoing the biofilm-forming test using the tissue culture plate method. Antibiotic susceptibility testing for each antibiotic was then performed using the disc diffusion method. Results: The incidence of antibiotic resistance to clindamycin in BF and NBF C. acnes isolates was 54.5% (p=1.00), while in BF and NBF S. epidermidis isolates, it was 54.5% and 45.5% respectively (p=0.67). The incidence of antibiotic resistance to erythromycin and azithromycin in BF and NBF C. acnes isolates was 54.5% and 63.6% respectively (p=1.00), whereas for S. epidermidis BF and NBF isolates, it was 54.5% (p=1.00). There was no resistance observed to tetracycline, doxycycline, levofloxacin, and cotrimoxazole in all groups. Conclusion: There were no significant differences in resistance against seven antibiotics between the C. acnes and S. epidermidis in BF and NBF groups. Furthermore, although statistically not significant, some resistances were observed against clindamycin, erythromycin, and azithromycin. Consequently, the use of these three antibiotics should be judiciously regulated.

Verified
Journal Article
Open access
PDF file
MYMuhammad Yusuf
Muhammad Yusuf
WDWanda Destiarani
Wanda Destiarani
AFAde Rizqi Ridwan Firdaus
Ade Rizqi Ridwan Firdaus
Fauzian Giansyah Giansyah rohmatullohFauzian Giansyah Giansyah rohmatulloh
Fauzian Giansyah Giansyah rohmatulloh
MNMia Tria Novianti
Mia Tria Novianti
RDReiva Farah Dwiyana
Reiva Farah Dwiyana
LL-37 is a membrane-active antimicrobial peptide (AMP) that could disrupt the integrity of bacterial membranes due to its inherent cationic and amphipathic nature. Developing a shorter derivative of a long peptide such as LL-37 is of great interest, as it can reduce production costs and cytotoxicity. However, more detailed information about the residual interaction between LL-37 and the membrane is required for further optimization. Previously, molecular dynamics simulation using mixed all-atom and united-atom force fields showed that LL-37 could penetrate the bilayer membrane. This study aimed to perform all-atom molecular dynamics simulations, highlighting the residual interaction of LL-37 with the simplest model of the bacterial membrane, POPE:POPG (2:1), and compare its interaction with the POPC, which represents the eukaryotic membrane. The result showed leucine–leucine as the leading residues of LL-37 that first contact the membrane surface. Then, the cationic peptide of LL-37 started to penetrate the membrane by developing salt bridges between positively charged amino acids, Lys–Arg, and the exposed phosphate group of POPE:POPG, which is shielded in POPC. Residues 18 to 29 are suggested as the core region of LL-37, as they actively interact with the POPE:POPG membrane, not POPC. These results could provide a basis for modifying the amino acid sequence of LL-37 and developing a more efficient design for LL-37 derivatives.

6 August 2022 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
RERaden Mohamad Rendy Ariezal Effendi
Raden Mohamad Rendy Ariezal Effendi
TRTrustia Rizqandaru
Trustia Rizqandaru
RYRenata Yuliasari
Renata Yuliasari
SGSrie Prihianti Gondokaryono
Srie Prihianti Gondokaryono
IDInne Arline Diana
Inne Arline Diana
RDReiva Farah Dwiyana
Reiva Farah Dwiyana
Non-Langerhans cell histiocytosis (non-LCH) is a group of diseases characterized by the proliferation of histiocytes in tissues that is excluded from the diagnostic criteria for LCH. Juvenile xanthogranuloma (JXG) and benign cephalic histiocytosis (BCH) are the most common types of cutaneous non-LCH. These two diseases share similarities in both clinical and histological features, therefore, they can be difficult to differentiate. Thorough physical, dermoscopic, and histopathological examinations are required to distinguish between JXG and BCH. We hereby present two rare cases of non-LCH in pediatric patients, presented with JXG and BCH. The dermoscopic examination of both cases showed a setting-sun appearance, while the histopathological examination revealed Touton giant cells in the JXG case, and massive lymphocyte infiltration in the BCH case. Both patients were treated with 1% topical rapamycin in a split-side comparison for the first 12 weeks, followed by applications on both sides for a total duration of 24 weeks. As a result, there was a significant reduction in the size of the lesion, leading to patient’s satisfaction. Rapamycin is an immunosuppressive agent with antineoplastic activity. Rapamycin can be used as an alternative non-invasive topical treatment option for JXG and BCH. However, long-term observations are required to assess its effectiveness and side effects.

7 July 2022 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
ACAnis Yohana Chaerunisaa
Anis Yohana Chaerunisaa
MDMayang Kusuma Dewi
Mayang Kusuma Dewi
SRSriwidodo
Sriwidodo
IJI Made Joni
I Made Joni
RDReiva Farah Dwiyana
Reiva Farah Dwiyana
Objective: The purpose of this study was to produce an optimum liposome formulation and to study the effect of formulation parameter such as phospholipid amount and hydration time on characteristics of liposome containing Cathelichidin. Methods: Liposomes were prepared using a thin layer hydration method. Characterization of liposomes included organoleptic, PSA (Particle Size Analyzer) and zeta potential, entrapment efficiency, morphology by TEM (Transmission Electron Microscopy), the chemical interaction by FTIR (Fourier Transform Infrared Spectroscopy), and the stability by using Freeze-Thaw method. Results: The result of the organoleptic test showed that the liposome were in the form of milky white dispersion, odorless, and without sedimentation. Optimum formula was obtained by making variations of soy oil: cholesterol 10: 0 (F1), 9: 1 (F2), 8: 2 (F3), 7: 3 (F4), and variations in sonication time (10 and 30 min). Based on the results, it was found that the optimum sonication time was 30 min. F2 and F3 were chosen as the most optimum formulas with particle sizes of 190.3±6.8 nm and 212.9±4.4 nm; polydispersity index of 0.192±0.023 and 0.137±0.022, and zeta potential as much as-38.8±0.6 mV and-34.8±2.0 mV. To the optimum formula, cathelicidin was loaded with hydration time varies of 100 and 120 min. Longer hydration time resulted in smaller particle size and higher entrapment efficiency either for F2 or F3. TEM characterization revealed a spherical shape of liposomes from the optimum formula. The results of FTIR characterization did not show any interaction between the phospholipids of liposomes with cathelicidin. The data from the stability test showed good stability for F2 and F3 with a hydration time of 120 min, indicated by a p-value>0.05, which indicated that there was no significant change in the zeta potential for three Freeze-Thaw cycles. Conclusion: Formula of liposom using a variation of soy oil: cholesterol 9:1 and 8:2 with hydration time of 120 min revealed the best result with good stability for three Freeze-Thaw cycles.